High levels of PD-L1 on platelets of NSCLC patients contributes to the pharmacological activity of Atezolizumab.
Colarusso C, Falanga A, Terlizzi M, De Rosa I, Somma P, Sommella EM, Caponigro V, Panico L, Salviati E, Campiglia P, Salatiello G, Tramontano T, Maiolino P, Pinto A, Sorrentino R.
Colarusso C, et al. Among authors: terlizzi m.
Biomed Pharmacother. 2023 Dec;168:115709. doi: 10.1016/j.biopha.2023.115709. Epub 2023 Oct 18.
Biomed Pharmacother. 2023.
PMID: 37857253
Free article.